Orbactiv (oritavancin) is an intravenously administered drug treating ABSSSI infections caused by susceptible bacteria such as Staphylococcus aureus, MRSA, Streptococcus species and Enterococcus faecalis, according to a news release.
This is the third antibacterial drug the FDA has approved this year to treat ABSSSI. Dalvance (dalbavancin) was approved in May and Sivextro (tedizolid) was approved in June, according to the news release.
Orbactiv was designated as a Qualified Infectious Disease Product due to its intention to treat serious or life-threatening infection. Due to its designation, the drug was given priority review, including an expedited review of its application.
More articles on the FDA:
Quicker FDA drug approval leads to increased drug withdrawals
What the latest FDA guidance means for mHealth
FDA proposes exempting certain devices from premarket requirements
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
